Compare Moderna, Inc. (MRNA) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Moderna, Inc. trades at $224.78 (market cap $78.65B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.97 (market cap $2.03B). The key difference: Moderna, Inc. is far larger — about 38.7× Direxion Daily 20 Year Treasury Bull 3X Shares's market cap, and Moderna, Inc. is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days on average.
| MRNA | TMF | |
|---|---|---|
Market Cap | $78.65B | $2.03B |
Volume | 37,373,437 | 12,241,664 |
Sector | Health | Fixed Income |
52-Week High | $203.46 | $44.14 |
52-Week Low | $22.36 | $25.19 |
Typical Hold Time | 59 Days | 28 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $25.93, up 2.75% with elevated volume. Technical indicators show a bearish trend from moving averages, though oscillators are neutral. The ETF saw increased trading interest recently, with support at $25 and resistance at $26.
As a leveraged ETF tracking long-term Treasuries, TMF's outlook hinges on interest rate trends. Opportunities exist if rates fall, but risks include rate hikes and volatility decay. Investors should monitor Fed policy for directional cues amid current bearish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
